Same name, different game: EGFR drives intrinsic KRASG12C inhibitor resistance in colorectal cancer

Mohamad Karim Koleilat; Lawrence N. Kwong

doi:10.1158/2159-8290.CD-20-0612

Same name, different game: EGFR drives intrinsic KRAS^G12C inhibitor resistance in colorectal cancer

Mohamad Karim Koleilat, Lawrence N. Kwong

Translational Molecular Pathology

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

The discovery of covalent inhibitors of KRAS^G12C has led to promising clinical results in lung cancer, but disappointing response rates in colon cancer. In this issue of Cancer Discovery, Misale and colleagues identify high endogenous EGFR activity as the underlying mechanism of intrinsic resistance, which can be overcome by anti-EGFR antibody coadministration.

Original language	English (US)
Pages (from-to)	1094-1096
Number of pages	3
Journal	Cancer discovery
Volume	10
Issue number	8
DOIs	https://doi.org/10.1158/2159-8290.CD-20-0612
State	Published - 2020

ASJC Scopus subject areas

Oncology

Access to Document

10.1158/2159-8290.CD-20-0612

Cite this

@article{b8f8462f0b4b404086c557e72cf5c7b9,

title = "Same name, different game: EGFR drives intrinsic KRASG12C inhibitor resistance in colorectal cancer",

abstract = "The discovery of covalent inhibitors of KRASG12C has led to promising clinical results in lung cancer, but disappointing response rates in colon cancer. In this issue of Cancer Discovery, Misale and colleagues identify high endogenous EGFR activity as the underlying mechanism of intrinsic resistance, which can be overcome by anti-EGFR antibody coadministration.",

author = "Koleilat, {Mohamad Karim} and Kwong, {Lawrence N.}",

note = "Publisher Copyright: {\textcopyright} 2020 American Association for Cancer Research.",

year = "2020",

doi = "10.1158/2159-8290.CD-20-0612",

language = "English (US)",

volume = "10",

pages = "1094--1096",

journal = "Cancer discovery",

issn = "2159-8274",

publisher = "American Association for Cancer Research Inc.",

number = "8",

}

TY - JOUR

T1 - Same name, different game

T2 - EGFR drives intrinsic KRASG12C inhibitor resistance in colorectal cancer

AU - Koleilat, Mohamad Karim

AU - Kwong, Lawrence N.

PY - 2020

Y1 - 2020

N2 - The discovery of covalent inhibitors of KRASG12C has led to promising clinical results in lung cancer, but disappointing response rates in colon cancer. In this issue of Cancer Discovery, Misale and colleagues identify high endogenous EGFR activity as the underlying mechanism of intrinsic resistance, which can be overcome by anti-EGFR antibody coadministration.

AB - The discovery of covalent inhibitors of KRASG12C has led to promising clinical results in lung cancer, but disappointing response rates in colon cancer. In this issue of Cancer Discovery, Misale and colleagues identify high endogenous EGFR activity as the underlying mechanism of intrinsic resistance, which can be overcome by anti-EGFR antibody coadministration.

UR - http://www.scopus.com/inward/record.url?scp=85089060340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85089060340&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-20-0612

DO - 10.1158/2159-8290.CD-20-0612

M3 - Article

C2 - 32747369

AN - SCOPUS:85089060340

SN - 2159-8274

VL - 10

SP - 1094

EP - 1096

JO - Cancer discovery

JF - Cancer discovery

IS - 8

ER -

Same name, different game: EGFR drives intrinsic KRAS^G12C inhibitor resistance in colorectal cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this